SEC	Form	4
-----	------	---

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

O'Malley Brendan M.       ABEONA THERAPEUTICS INC. [ABEO]       (Check all applicable)         (Last)       (First)       (Middle)         6555 CARNEGIE AVE., 4TH FLOOR       3. Date of Carliest Transaction (Month/Day/Year)       Officer (give title Other (specify below)         (Street)       4. If Amendment, Date of Original Filed (Month/Day/Year)       6. Individual or Joint/Group Filing (Check Applicable Line)         X       Form filed by One Reporting Person			Table I - Non	-Derivative Securities Acquired, Disposed of, or Benefic	cially Owned				
O'Malley Brendan M.       ABEONA THERAPEUTICS INC. [ABEO]       (Check all applicable)         0'Malley Brendan M.       3. Date of Earliest Transaction (Month/Day/Year)       Director       10% Owner         3. Date of Earliest Transaction (Month/Day/Year)       06/06/2025       Other (specify below)         6555 CARNEGIE AVE., 4TH FLOOR       4. If Amendment, Date of Original Filed (Month/Day/Year)       6. Individual or Joint/Group Filing (Check Applicable Line)         (Street)       X       Form filed by One Reporting Person	(City)	(State)	(Zip)						
O'Malley Brendan M.     ABEONA THERAPEUTICS INC. [ABEO]     (Check all applicable)       3. Date of Earliest Transaction (Month/Day/Year)     Director     10% Owner       06/06/2025     06/06/2025     Officer (give title below)			44103	4. If Amendment, Date of Original Filed (Month/Day/Year)	<ul> <li>6. Individual or Joint/Group Filing (Check Applicable Line)</li> <li>X Form filed by One Reporting Person</li> <li>Form filed by More than One Reporting Person</li> </ul>				
O'Mailey Brendan M.       ABEONA THERAPEUTICS INC. [ABEO]       (Check all applicable)         3. Date of Earliest Transaction (Month/Day/Year)       Director       10% Owner         0/Mailey Brendan M.       0.00 (0025)       Officer (give title       Other (specify	6555 CARNEGI	E AVE., 4TH	FLOOR		SVP, General Counsel				
O'Malley Brendan M ABEONA THERAPEUTICS INC. [ABEO] (Check all applicable)	(Last)	(First)	(Middle)		X Officer (give title Other (specify				
			erson*	2. Issuer Name and Ticker or Trading Symbol <u>ABEONA THERAPEUTICS INC.</u> [ ABEO ]					

## 1. Title of Security (Instr. 3) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 2. Transaction 2A. Deemed 5. Amount of 6. Ownership 7. Nature of Form: Direct (D) Date Execution Date. Transaction Securities Indirect (Month/Day/Year) Code (Instr. Beneficially Owned or Indirect (I) Beneficial if any Following Reported Transaction(s) (Month/Dav/Year) 8) (Instr. 4) Ownership (Instr. 4) (A) or (Instr. 3 and 4) Code v Amount Price D) Common Stock 06/06/2025 **S**<sup>(1)</sup> 10,470 D \$6.76<sup>(2)</sup> 378,245 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1	Security (Instr. 3)		3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security (Instr. 5)		Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	(in	Transaction(s) (Instr. 4)		

Explanation of Responses:

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$6.76 to \$6.79 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

/s/ Brendan O'Malley

\*\* Signature of Reporting Person

06/06/2025

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Date